Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
1.
Pharm Res ; 33(10): 2506-16, 2016 10.
Article in English | MEDLINE | ID: mdl-27387171

ABSTRACT

PURPOSE: 1-phenyl piperazine (PPZ) emerged from a Caco-2 monolayer screen as having high enhancement potential due to a capacity to increase permeation without significant toxicity. Our aim was to further explore the efficacy and toxicity of PPZ in rat ileal and colonic mucosae in order to assess its true translation potential. METHODS: Intestinal mucosae were mounted in Ussing chambers and apparent permeability coefficient (Papp) values of [(14)C]-mannitol and FITC-dextran 4 kDa (FD-4) and transepithelial electrical resistance (TEER) values were obtained following apical addition of PPZ (0.6-60 mM). Exposed issues were assessed for toxicity by histopathology and lactate dehydrogenase (LDH) release. Mucosal recovery after exposure was also assessed using TEER readings. RESULTS: PPZ reversibly increased the Papp of both agents across rat ileal and distal colonic mucosae in concentration-dependent fashion, accompanied by TEER reduction, with acceptable levels of tissue damage. The complex mechanism of tight junction opening was part mediated by myosin light chain kinase, stimulation of transepithelial electrogenic chloride secretion, and involved activation of 5-HT4 receptors. CONCLUSIONS: PPZ is an efficacious and benign intestinal permeation enhancer in tissue mucosae. However, its active pharmacology suggest that potential for further development in an oral formulation for poorly permeable molecules will be difficult.


Subject(s)
Intestinal Mucosa/metabolism , Piperazines/administration & dosage , Piperazines/metabolism , Adrenergic alpha-Antagonists/administration & dosage , Adrenergic alpha-Antagonists/metabolism , Animals , Caco-2 Cells , Humans , Intestinal Mucosa/drug effects , Male , Organ Culture Techniques , Permeability/drug effects , Rats , Rats, Wistar
2.
Pharm Res ; 29(9): 2543-54, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22638869

ABSTRACT

PURPOSE: CriticalSorb™ is a novel absorption enhancer based on Solutol(®) HS15, one that has been found to enhance the nasal transport. It is in clinical trials for nasal delivery of human growth hormone. The hypothesis was that permeating enhancement effects of the Solutol(®)HS15 component would translate to the intestine. METHODS: Rat colonic mucosae were mounted in Ussing chambers and Papp values of [(14)C]-mannitol, [(14)C]-antipyrine, FITC-dextran 4000 (FD-4), and TEER values were calculated in the presence of CriticalSorb™. Tissues were fixed for H & E staining. Caco-2 monolayers were grown on Transwells™ for similar experiments. RESULTS: CriticalSorb™(0.01% v/v) significantly increased the Papp of [(14)C]-mannitol, FD-4 [(14)C]-antipyrine across ileal and colonic mucosae, accompanied by a decrease in TEER. In Caco-2 monolayers, it also increased the Papp of [(14)C]-mannitol FD-4 and [(14)C]-antipyrine over 120 min. In both monolayers and tissues, it acted as a moderately effective P-glycoprotein inhibitor. There was no evidence of cytotoxicity in Caco-2 at concentrations of 0.01% for up to 24 h and histology of tissues showed intact epithelia at 120 min. CONCLUSIONS: Solutol(®) HS15 is the key component in CriticalSorb™ that enables non-cytotoxic in vitro intestinal permeation and its mechanism of action is a combination of increased paracellular and transcellular flux.


Subject(s)
Intestinal Mucosa/metabolism , Animals , Caco-2 Cells , Humans , Male , Rats , Rats, Wistar
3.
AAPS J ; 22(2): 33, 2020 01 27.
Article in English | MEDLINE | ID: mdl-31989362

ABSTRACT

A limiting factor for oral delivery of macromolecules is low intestinal epithelial permeability. 1-Phenylpiperazine (PPZ), 1-(4-methylphenyl) piperazine (1-4-MPPZ) and 1-methyl-4-phenylpiperazine (1-M-4-PPZ) have emerged as potential permeation enhancers (PEs) from a screen carried out by others in Caco-2 monolayers. Here, their efficacy, mechanism of action and potential for epithelial toxicity were further examined in Caco-2 cells and isolated rat intestinal mucosae. Using high-content analysis, PPZ and 1-4-MPPZ decreased mitochondrial membrane potential and increased plasma membrane potential in Caco-2 cells to a greater extent than 1-M-4-PPZ. The Papp of the paracellular marker, [14C]-mannitol, and of the peptide, [3H]-octreotide, was measured across rat colonic mucosae following apical addition of the three piperazines. PPZ and 1-4-MPPZ induced a concentration-dependent decrease in transepithelial electrical resistance (TEER) and an increase in the Papp of [14C]-mannitol without causing histological damage. 1-M-4-PPZ was without effect. The piperazines caused the Krebs-Henseleit buffer pH to become alkaline, which partially attenuated the increase in Papp of [14C]-mannitol caused by PPZ and 1-4-MPPZ. Only addition of 1-4-MPPZ increased the Papp of [3H]-octreotide. Pre-incubation of mucosae with two 5-HT4 receptor antagonists, a loop diuretic and a myosin light chain kinase inhibitor, reduced the permeation enhancement capacity of PPZ and 1-4-MPP for [14C]-mannitol. 1-4-MPPZ holds most promise as a PE, but intestinal physiology may also be impacted due to multiple mechanisms of action.


Subject(s)
Colon/drug effects , Intestinal Absorption/drug effects , Intestinal Mucosa/drug effects , Piperazines/pharmacology , Animals , Caco-2 Cells , Colon/metabolism , Dose-Response Relationship, Drug , Electric Impedance , Humans , Intestinal Mucosa/metabolism , Male , Permeability , Rats, Wistar
4.
Adv Drug Deliv Rev ; 157: 2-36, 2020.
Article in English | MEDLINE | ID: mdl-32479930

ABSTRACT

In its 33 years, ADDR has published regularly on the po5tential of oral delivery of biologics especially peptides and proteins. In the intervening period, analysis of the preclinical and clinical trial failures of many purported platform technologies has led to reflection on the true status of the field and reigning in of expectations. Oral formulations of semaglutide, octreotide, and salmon calcitonin have completed Phase III trials, with oral semaglutide being approved by the FDA in 2019. The progress made with oral peptide formulations based on traditional permeation enhancers is against a background of low and variable oral bioavailability values of ~1%, leading to a current perception that only potent peptides with a viable cost of synthesis can be realistically considered. Desirable features of candidates should include a large therapeutic index, some stability in the GI tract, a long elimination half-life, and a relatively low clearance rate. Administration in nanoparticle formats have largely disappointed, with few prototypes reaching clinical trials: insufficient particle loading, lack of controlled release, low epithelial particle uptake, and lack of scalable synthesis being the main reasons for discontinuation. Disruptive technologies based on engineered devices promise improvements, but scale-up and toxicology aspects are issues to address. In parallel, medicinal chemists are synthesizing stable hydrophobic macrocyclic candidate peptides of lower molecular weight and with potential for greater oral bioavailability than linear peptides, but perhaps without the same requirement for elaborate drug delivery systems. In summary, while there have been advances in understanding the limitations of peptides for oral delivery, low membrane permeability, metabolism, and high clearance rates continue to hamper progress.


Subject(s)
Chemistry, Pharmaceutical/methods , Drug Delivery Systems , Peptides/administration & dosage , Administration, Oral , Animals , Biological Availability , Humans , Hydrophobic and Hydrophilic Interactions , Peptides/chemistry , Peptides/pharmacokinetics , Proteins/administration & dosage , Proteins/chemistry , Proteins/pharmacokinetics
5.
Neuropathol Appl Neurobiol ; 35(6): 592-602, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19486302

ABSTRACT

AIMS: In human immunodeficiency virus infection, macrophage-tropic and lymphotropic viruses exist in the host. Central nervous system (CNS) infection is an early and ongoing event, important to understand when developing strategies to treat infection. Some knowledge exists on macrophage-tropic virus interactions with the blood-brain barrier (BBB), and the aim of this study was to investigate lymphotropic lentivirus interactions with the BBB. METHODS: Interactions of the lymphotropic feline immunodeficiency virus (FIV) with an in vitro model of the feline BBB were evaluated in scenarios to mimic in vivo infections. RESULTS: Cell-free FIV crossed the BBB in very low quantities, and in the presence of tumour necrosis factor (TNF)-alpha, BBB integrity was unaffected. However, cell-associated FIV readily crossed the BBB, but BBB integrity was not significantly altered. Transmigration of uninfected and infected lymphocytes increased in response to TNF-alpha, accompanied by a moderate disruption of barrier integrity and an upregulation of vascular cell adhesion molecule-1 rather than intercellular adhesion molecule-1. Significant enhancement of migration and disruption of BBB tight junctions occurred when infected cells and TNF-alpha were added to the brain side of the BBB and this enhancement was not mediated through additional TNF-alpha production. CONCLUSIONS: Small quantities of virus in the brain together with TNF-alpha have the potential to stimulate greater cell and viral entry into the CNS and this is likely to involve important factors other than further TNF-alpha production. Lymphotropic lentivirus entry to the CNS is governed by many factors similar to macrophage-tropic strains.


Subject(s)
Blood-Brain Barrier/physiopathology , Blood-Brain Barrier/virology , CD4-Positive T-Lymphocytes/physiology , CD4-Positive T-Lymphocytes/virology , Feline Acquired Immunodeficiency Syndrome/physiopathology , Feline Acquired Immunodeficiency Syndrome/virology , Immunodeficiency Virus, Feline/physiology , Tumor Necrosis Factor-alpha/metabolism , Animals , Astrocytes/physiology , Brain/physiopathology , Brain/virology , Cats , Cell Line , Cell Movement , Cells, Cultured , Endothelial Cells/physiology , Intercellular Adhesion Molecule-1/metabolism , Lymphocyte Activation , Tight Junctions/physiology , Up-Regulation , Vascular Cell Adhesion Molecule-1/metabolism
6.
Adv Drug Deliv Rev ; 136-137: 2-27, 2018.
Article in English | MEDLINE | ID: mdl-30359631

ABSTRACT

Current treatments for intestinal diseases including inflammatory bowel diseases, irritable bowel syndrome, and colonic bacterial infections are typically small molecule oral dosage forms designed for systemic delivery. The intestinal permeability hurdle to achieve systemic delivery from oral formulations of macromolecules is challenging, but this drawback can be advantageous if an intestinal region is associated with the disease. There are some promising formulation approaches to release peptides, proteins, antibodies, antisense oligonucleotides, RNA, and probiotics in the colon to enable local delivery and efficacy. We briefly review colonic physiology in relation to the main colon-associated diseases (inflammatory bowel disease, irritable bowel syndrome, infection, and colorectal cancer), along with the impact of colon physiology on dosage form design of macromolecules. We then assess formulation strategies designed to achieve colonic delivery of small molecules and concluded that they can also be applied some extent to macromolecules. We describe examples of formulation strategies in preclinical research aimed at colonic delivery of macromolecules to achieve high local concentration in the lumen, epithelial-, or sub-epithelial tissue, depending on the target, but with the benefit of reduced systemic exposure and toxicity. Finally, the industrial challenges in developing macromolecule formulations for colon-associated diseases are presented, along with a framework for selecting appropriate delivery technologies.


Subject(s)
Colon/metabolism , Colonic Diseases/drug therapy , Drug Delivery Systems , Macromolecular Substances/administration & dosage , Macromolecular Substances/pharmacokinetics , Humans , Macromolecular Substances/therapeutic use
7.
Adv Drug Deliv Rev ; 106(Pt B): 223-241, 2016 11 15.
Article in English | MEDLINE | ID: mdl-26921819

ABSTRACT

The development of oral dosage forms that allows absorption of therapeutic peptides to the systemic circulation is one of the greatest challenges for the pharmaceutical industry. Currently, a number of technologies including either mixtures of penetration enhancers or protease inhibitors and/or nanotechnology-based products are under clinical development. Typically, these formulations are presented in the form of enteric-coated tablets or capsules. Systems undergoing preclinical investigation include further advances in nanotechnology, including intestinal microneedle patches, as well as their combination with regional delivery to the colon. This review critically examines four selected promising oral peptide technologies at preclinical stage and the twelve that have progressed to clinical trials, as indicated in www.clinicaltrials.gov. We examined these technologies under the criteria of peptide selection, formulation design, system components and excipients, intestinal mechanism of action, efficacy in man, and safety issues. The conclusion is that most of the technologies in clinical trials are incremental rather than paradigm-shifting and that even the more clinically advanced oral peptide drugs examples of oral bioavailability appear to yield oral bioavailability values of only 1-2% and are, therefore, only currently suitable for a limited range of peptides.


Subject(s)
Drug Delivery Systems , Intestinal Absorption , Peptides/administration & dosage , Peptides/pharmacokinetics , Administration, Oral , Animals , Biological Availability , Clinical Trials as Topic , Excipients/administration & dosage , Excipients/pharmacokinetics , Humans
8.
Microbes Infect ; 3(10): 867-76, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11580982

ABSTRACT

Entrapment of antigens in biodegradable particles for mucosal immunisation has given successful outcomes in animals, but not as yet in man. Formulations using genuinely stable biocompatible nanoparticles with co-entrapped mucosal adjuvants and/or with surface-conjugated human M-cell-targeting ligands may lead to better uptake of intact antigen by Peyer's patch M cells and delivery to antigen-presenting cells.


Subject(s)
Immunity, Mucosal , Vaccines, Subunit/immunology , Administration, Oral , Animals , Antigen-Presenting Cells/immunology , Drug Delivery Systems , Humans , Liposomes , Particle Size , Peyer's Patches/immunology , Vaccines, Subunit/administration & dosage
9.
Proc Biol Sci ; 245(1312): 53-8, 1991 Jul 22.
Article in English | MEDLINE | ID: mdl-1682929

ABSTRACT

Cultured monolayers of human sweat-gland epithelia have been used to measure electrogenic sodium transport, as short-circuit current, and intracellular Ca2+ concentration ([Ca]i) from Fura-2 fluorescence. The sodium currents in response to the agonists lysylbradykinin, histamine and carbachol show oscillatory behaviour in the 1-2 per minute frequency range. The oscillations can be terminated either by using specific antagonists or with amiloride, which prevents sodium entry into the epithelium. Oscillatory behaviour is also seen when [Ca]i is measured and occurs in the same frequency range. Sodium transport in these cultured epithelia is thought to result from an increase in [Ca]i, which in turn activates calcium-sensitive potassium channels, so increasing the electrochemical gradient for sodium entry. The oscillatory behaviour implies that the epithelial cells behave in synchrony to increase [Ca]i, so inducing synchronous changes in sodium current. It is shown that the behaviour is not unique to sodium-absorbing epithelia, and the possible utility of synchronous behaviour in epithelial tissues is discussed.


Subject(s)
Calcium/metabolism , Sodium/metabolism , Sweat Glands/metabolism , Adenosine Triphosphate/pharmacology , Biological Transport, Active/drug effects , Carbachol/pharmacology , Culture Techniques , Epithelium/drug effects , Epithelium/metabolism , Histamine/pharmacology , Humans , Intracellular Fluid/metabolism , Kallidin/pharmacology , Sweat Glands/drug effects
10.
Br J Pharmacol ; 113(2): 593-9, 1994 Oct.
Article in English | MEDLINE | ID: mdl-7530575

ABSTRACT

1. Rabbit small intestinal segments containing Peyer's patches (PP) were examined in Ussing chambers using short-circuit current (Isc) recording. By comparison with control small intestinal mucosal segments, rabbit PP-containing epithelia exhibited decreased basal Isc, increased transepithelial resistance (TER) and unchanged potential difference (PD). 2. Carbachol caused a decrease in Isc in rabbit PP epithelia. Forskolin, dibutyryl cyclic GMP, histamine and the calcium ionophore, A23187, were without effect. In contrast, control epithelial segments of rabbit intestine responded to carbachol and forskolin with an increased Isc, indicative of electrogenic chloride secretion. The EC50 for carbachol was approximately 2 microM in both types of epithelia. Methacholine also caused an outward current in rabbit PP epithelia which had similar properties to that of carbachol. The effect of the cholinomimetics on rabbit PP was basolateral-sided, reversible, and sensitive to low concentrations of the general muscarinic cholinoceptor blockers, atropine, scopolamine and also to the M1 cholinoceptor blocker, pirenzepine. 3. The Isc response to cholinomimetics in rabbit PP was insensitive to bumetanide, amiloride, TEA, barium, acetazolamide, piroxicam and omeprazole, but was attenuated in the presence of ouabain. Using bilaterally-substituted solutions, the carbachol effect on rabbit PP Isc was abolished in chloride/bicarbonate-free, but not in chloride-free solutions, suggestive of stimulation of electrogenic bicarbonate absorption by the agent. Substitution for sodium abolished both the basal current and the Isc response to carbachol. Part of the effect of carbachol on PP Isc appeared to be mediated by submucosal neurones because addition of tetrodotoxin reduced the effect by 60%. 4 As microfold (M) epithelial cells predominate in the PP of the rabbit, the unusual phenotype of cholinomimetic-induced outward current may be used as an electrophysiological marker for these potential sites of oral vaccine delivery, and in particular it may also be of use as a marker for rabbit M cells.


Subject(s)
Intestines/physiology , Peyer's Patches/physiology , Animals , Carbachol/pharmacology , Cholinergic Agents/pharmacology , Electrophysiology , Epithelium/drug effects , Epithelium/metabolism , Female , In Vitro Techniques , Intestines/drug effects , Ion Channels/drug effects , Ion Channels/metabolism , Male , Methacholine Chloride/pharmacology , Peyer's Patches/drug effects , Rabbits , Tetrodotoxin/pharmacology
11.
Br J Pharmacol ; 102(1): 57-64, 1991 Jan.
Article in English | MEDLINE | ID: mdl-1646063

ABSTRACT

1. Cultured epithelia derived from whole human sweat glands, isolated secretory coils, isolated reabsorptive ducts and whole glands from cystic fibrosis (CF) subjects have been used to examine drug sensitivity by use of short circuit current recording. 2. Short circuit current increases were observed with lysylbradykinin, carbachol and histamine in epithelia of different origins. All responses were due to stimulation of electrogenic sodium absorption, evidenced by the inhibition of these responses by amiloride. The latter also abolished the basal current. The terpenes, thapsigargin and forskolin had no effect on transport. 3. The stimulation of a sodium current by agonists was dependent upon calcium, responses being inhibited by lanthanum ions and EGTA. Further A23187 induced a sodium current. 4. Pronounced oscillations in the sodium currents were a feature of the responses, implying synchronous, regulated cell activity. 5. Forskolin produced a ten fold increase in adenylate cyclase activity. All agonists listed in 2 except forskolin caused an increase in intracellular calcium [Ca]i, [Ca]i responses in CF cells were not different from those of normal cells, except with thapsigargin where the responses were smaller. 6. It is concluded that in culture, cells develop ductal characteristics, whether derived from normal or CF glands, coils or ducts. An increase in [Ca]i followed by activation of calcium-sensitive potassium channels and apical membrane hyperpolarization may be the major mechanism for increasing sodium influx.


Subject(s)
Cystic Fibrosis/metabolism , Sweat Glands/metabolism , Adenylyl Cyclases/drug effects , Adenylyl Cyclases/metabolism , Amiloride/pharmacology , Barium/pharmacology , Calcium/metabolism , Calcium/physiology , Carbachol/pharmacology , Cells, Cultured , Colforsin/pharmacology , Cyclic AMP/metabolism , Epithelium/drug effects , Epithelium/metabolism , Humans , Kallidin/pharmacology , Lanthanum/pharmacology , Sodium Channels/drug effects , Sweat Glands/drug effects , Terpenes/pharmacology , Thapsigargin
12.
Br J Pharmacol ; 98(3): 809-16, 1989 Nov.
Article in English | MEDLINE | ID: mdl-2511993

ABSTRACT

1. Thapsigargin, a sesquiterpene lactone, was shown to cause electrogenic anion secretion in monolayers of human colonic epithelial cells, an effect which was crucially dependent upon calcium and did not involve eicosanoid formation. 2. To measure the secretory effect calcium needed to be present in the external bathing solution. By means of Fura-2 fluorescence measurements thapsigargin was shown to raise Cai by around 250 nM when the bathing solution contained calcium. In the nominal absence of external calcium thapsigargin raised Cai by only 60 nM, but from a lower basal value. This was insufficient to cause secretion. 3. Effects of other calcium-dependent secretagogues (e.g. lysylbradykinin) were inhibited in the presence of thapsigargin, whereas kinin responses were potentiated if the peptide was added following a stimulus which increases cyclic AMP. 4. From the data given here and the known behaviour of colonic epithelia it is concluded that thapsigargin increases Cai by a non-ionophoric mechanism by release from internal stores. Calcium-stimulated calcium influx then follows resulting in the opening of basolateral K channels, increasing the electrochemical gradient for chloride efflux, or alternatively by activating anion channels in the apical membrane. It is concluded that thapsigargin is a potentially important tool for examining epithelial mechanisms.


Subject(s)
Calcium/physiology , Plant Extracts/pharmacology , Adenocarcinoma/metabolism , Anions/metabolism , Calcimycin/pharmacology , Colforsin/pharmacology , Colonic Neoplasms/metabolism , Electrophysiology , Epithelium/drug effects , Epithelium/metabolism , Humans , Thapsigargin , Tumor Cells, Cultured
13.
Eur J Pharm Sci ; 14(3): 183-9, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11576821

ABSTRACT

Over 30 publications suggest that antigens given orally to mice in biocompatible microspheres stimulate an immune response and, in some cases, can give rise to protective immunity. Of those responses in mice that have been reproduced, confirmation in large animal models and in Phase 1 studies has not resulted. Particles containing antigens given orally and mixed with soluble adjuvants like cholera toxin have generally not produced any better data in mice than that seen with mixed solutions of unprotected antigens and adjuvants. Peyer's patch M cell targeting of antigens in particles remains however a relatively untested hypothesis. While binding and uptake of M cell-targeted latex particles and stable liposomes by mouse M cells has been clearly shown using the mouse M cell-specific lectin, Ulex europaeus 1 (UEA-1), a direct relationship between M cell particle uptake and immune outcome remains illusive. Some studies have produced increased serum antibodies from UEA-1- and cholera toxin B (CTB)-coated liposomes containing antigens. Other groups are currently working on developing novel human M cell ligands for attachment to stable particles for oral delivery. Use of untargeted antigen-containing particles with adjuvants administered by the nasal route remains an alternative option.


Subject(s)
Antigens/administration & dosage , Plant Lectins , Vaccination , Adjuvants, Immunologic/administration & dosage , Administration, Oral , Animals , Antigens/immunology , Drug Delivery Systems , Humans , Lectins , Liposomes , Microspheres , Peyer's Patches/metabolism
14.
Adv Exp Med Biol ; 290: 253-69; discussion 269-72, 1991.
Article in English | MEDLINE | ID: mdl-1719763

ABSTRACT

The human genetic disease cystic fibrosis is caused by a single defective gene on chromosome 7 that codes for a 1480 amino acid protein called the cystic fibrosis transmembrane conductance regulator (CFTR). The defect causes a profound reduction of Cl- permeability in several tissues, which in turn impairs salt absorption and fluid secretion. A 25-80 pS, rectifying Cl- channel has been targeted as the exclusive or primary channel affected in CF. However, we have found no evidence for significant activation or spontaneous activity of this channel in cell-attached patches of normal lymphoblasts or dog tracheal cells. However, in dog tracheal cells, we find lower conductance, linear Cl- channels that are spontaneously active in unstimulated cells and may show increased activity in stimulated cells. Attempts to correlate the expression of mRNA for the CFTR protein in various types of cells with the presence of the rectifying Cl- channel show a lack of correlation: i.e., depolarization-activated rectifying Cl- channesl have been found in excised, inside-out patches from all cell types that we have examined to date, but the CFTR mRNA has so far only been detected in a subset of epithelial cells.


Subject(s)
Cystic Fibrosis/metabolism , Membrane Proteins/metabolism , Animals , Chloride Channels , Chlorides/metabolism , Cystic Fibrosis/genetics , Cystic Fibrosis Transmembrane Conductance Regulator , Humans , Ion Channels/metabolism , Membrane Proteins/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism
15.
Food Chem Toxicol ; 50(11): 4097-102, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22906760

ABSTRACT

The gastrointestinal lumen is directly exposed to dietary contaminants, including patulin, a mycotoxin produced by moulds. Patulin is known to increase permeability across intestinal Caco-2 monolayers. This study aimed to determine the effect of patulin on permeability, ion transport and morphology in isolated rat colonic mucosae. Mucosal sheets were mounted in Ussing chambers and voltage clamped. Apical addition of patulin (100-500 µM) rapidly reduced transepithelial electrical resistance (TEER) and increased permeability to [(14)C] mannitol (2.9-fold). Patulin also inhibited carbachol-induced electrogenic chloride secretion and histological evidence of mucosal damage was observed. To examine potential mechanisms of action of patulin on colonic epithelial cells, high-content analysis of Caco-2 cells was performed and this novel, quantitative fluorescence-based approach confirmed its cytotoxic effects. With regard to time course, the cytotoxicity determined by high content analysis took longer than the almost immediate reduction of electrical resistance in isolated mucosal sheets. These data indicate patulin is not only cytotoxic to enterocytes but also has the capacity to directly alter permeability and ion transport in intact intestinal mucosae. These data corroborate and extend findings in intestinal cell culture monolayers, and further suggest that safety limits on consumption of patulin may be warranted.


Subject(s)
Colon/drug effects , Intestinal Mucosa/drug effects , Patulin/pharmacokinetics , Patulin/toxicity , Animals , Caco-2 Cells/drug effects , Colon/cytology , Dose-Response Relationship, Drug , Humans , In Vitro Techniques , Intestinal Mucosa/metabolism , Ion Transport , Male , Mannitol/pharmacokinetics , Membrane Potential, Mitochondrial/drug effects , Permeability/drug effects , Rats , Rats, Wistar
16.
J Vet Pharmacol Ther ; 28(3): 257-65, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15953199

ABSTRACT

The transport of the antiparasitic agents, ivermectin, selamectin and moxidectin was studied in human intestinal epithelial cell monolayers (Caco-2) and canine peripheral blood lymphocytes (PBL). Both models expressed the mdr1-coded 170 kDa ATP-binding cassette (ABC) transporter P-glycoprotein (P-gp). Fluxes of the P-gp substrate rhodamine-123 (Rh-123) across Caco-2 monolayers showed that ivermectin and selamectin acted as potent P-gp inhibitors with IC50 values of 0.1 microm. In contrast, moxidectin was a weaker P-gp inhibitor with an IC50 of 10 microm. The transport of radiolabelled ivermectin, selamectin and moxidectin through Caco-2 monolayers showed that ivermectin, selamectin and moxidectin were P-gp substrates with secretory/absorptive ratios of 7.5, 4.7 and 2.6 respectively. Secretory transport of [3H]-ivermectin and [3H]-selamectin was blocked by the P-gp inhibitor, verapamil. Ivermectin and selamectin inhibited the efflux of Rh-123 from PBL and the concentration of inhibition was similar to that of verapamil. In contrast, moxidectin did not have a significant effect on Rh-123 efflux from PBL. The data suggest that ivermectin and selamectin are potent P-gp substrates, while moxidectin is a weak one.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Antiparasitic Agents/pharmacology , Ivermectin/analogs & derivatives , Ivermectin/pharmacology , ATP Binding Cassette Transporter, Subfamily B, Member 1/antagonists & inhibitors , ATP Binding Cassette Transporter, Subfamily B, Member 1/drug effects , Animals , Antiparasitic Agents/administration & dosage , Caco-2 Cells/drug effects , Caco-2 Cells/metabolism , Dogs , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Humans , Inhibitory Concentration 50 , Ivermectin/administration & dosage , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Macrolides/administration & dosage , Macrolides/pharmacology , Rhodamines/metabolism
17.
Br J Clin Pharmacol ; 29(2): 235-8, 1990 Feb.
Article in English | MEDLINE | ID: mdl-2306416

ABSTRACT

A new method is described to produce epithelial sheets by direct explantation of human sweat glands onto matrigel-coated millipore filters. The method is applicable to whole glands, separated coils or ducts and to normal and CF tissues. Electrogenic transport studies show that epithelia develop sodium transporting capability, even when explants are derived from secretory coils.


Subject(s)
Cystic Fibrosis/metabolism , Sweat Glands/metabolism , Culture Techniques , Epithelial Cells , Epithelium/metabolism , Humans , Sodium/metabolism , Sweat Glands/drug effects
18.
J Physiol ; 405: 657-75, 1988 Nov.
Article in English | MEDLINE | ID: mdl-3255802

ABSTRACT

1. Isolated human eccrine sweat glands were cultured in vitro. Cells were harvested and plated onto permeable supports to form confluent cell sheets, area 0.2 cm2. These were used to study the electrogenic transepithelial transport of ions by measurement of short-circuit current (SCC). Epithelial sheets had a basal SCC of 5.89 +/- 0.62 microA cm-2 (n = 33) and a transepithelial resistance of 74.1 +/- 5.6 omega cm2 (n = 33). The transepithelial potential difference varied between -0.2 and -1.8 mV with a mean value of -0.71 +/- 0.09 mV (n = 33). 2. The basal current was abolished by addition of 10 microM-amiloride to the apical bathing solution. The concentration of amiloride which inhibited basal SCC by 50% (EC50) was 0.4 microM. Cultures prepared from the secretory coil of sweat glands, rather than from whole glands, were similarly sensitive to amiloride (EC50 = 0.8 microM). 3. Lysylbradykinin (LBK), carbachol, isoprenaline, prostaglandin E2 (PGE2) and A23187 all increased SCC in cultures from whole glands. LBK responses were obtained with basolateral and not with apical application. Furthermore LBK actions were not substantially altered by cyclo-oxygenase inhibition but showed marked desensitization upon repeated application. Sheet cultures prepared from sweat gland coils also showed SCC responses to both carbachol and LBK. Forskolin, an activator of adenylate cyclase, did not alter SCC in either type of preparation. 4. Replacement of chloride and of chloride and bicarbonate in the bathing solution did not cause attenuation of the responses to LBK or carbachol in whole-gland sheet cultures. Furthermore responses were unaffected by piretanide or acetazolamide. These results were taken to indicate that anion secretion was not the basis for the SCC responses. 5. Responses to LBK and carbachol were significantly reduced by amiloride (10 microM), this effect being reversible. No responses to LBK or carbachol were seen when N-methyl-D-glucamine (NMDG) was used to replace sodium, whereas reintroduction of sodium ions restored responsiveness to these agents. 6. The SCC responses to the muscarinic agonist carbachol and to LBK appear to be due to stimulation of amiloride-sensitive, electrogenic sodium absorption in whole-gland sheet cultures. Further it would appear that, in culture, the pleuripotential capacity of the cells is revealed since both whole-gland and secretory coil cultures exhibit some properties usually associated in vivo with duct cells. Many mammalian epithelia show electrogenic chloride secretion both in response to carbachol and LBK but also in response to activation of adenylate cyclase with forskolin.(ABSTRACT TRUNCATED AT 400 WORDS)


Subject(s)
Sweat Glands/physiology , Amiloride/pharmacology , Bradykinin/pharmacology , Carbachol/pharmacology , Cells, Cultured , Colforsin/pharmacology , Epithelium/metabolism , Humans , Isoproterenol/pharmacology , Membrane Potentials/drug effects , Piroxicam/pharmacology , Sodium/metabolism , Sweat Glands/metabolism
19.
Br J Clin Pharmacol ; 29(2): 227-34, 1990 Feb.
Article in English | MEDLINE | ID: mdl-2306415

ABSTRACT

1. Using cultured epithelia from sweat glands, derived from both cystic fibrosis and normal subjects, the relationship between amiloride concentration and the inhibition of electrogenic sodium transport was measured, under short circuit conditions. 2. The Kd for amiloride in cultures from normal subjects was 0.64 microM (n = 6) while in cultures derived from CF patients the value was 1.07 microM (n = 4). The values were significantly different (P less than 0.02, ANOVA). 3. In cultures from normal sweat glands, bathed in solutions free of permeable anions (chloride/bicarbonate), the Kd for amiloride rose to a value greater than found in CF tissues (2.3 microM). In CF epithelia subject to the same conditions the abnormally high value increased further, so that in solutions without permeable anions normal and CF cultures behaved similarly. 4. In cultures derived from normal and CF tissues lowering the sodium concentration to 10 mM also lowered the Kd for amiloride, however the shift was greater for CF cultures. 5. Several possible explanations for the results are discussed. The most probable is that the relatively more positive apical membrane potential in CF epithelia opposes the interaction of amiloride with the sodium channel, implying that complex formation is potential sensitive.


Subject(s)
Amiloride/pharmacology , Cystic Fibrosis/metabolism , Sweat Glands/metabolism , Adolescent , Adult , Amiloride/metabolism , Child , Culture Techniques , Humans , Models, Biological , Sodium/metabolism , Sweat Glands/drug effects
20.
Vaccine ; 19(15-16): 1940-50, 2001 Feb 28.
Article in English | MEDLINE | ID: mdl-11228364

ABSTRACT

The immunogenicity and protective efficacy of systemically and orally delivered pertussis antigens entrapped in either microparticle poly-lactide-co-glycolide (PLG) or nanoparticle PLG formulations were evaluated in a murine respiratory challenge model for infection with Bordetella pertussis. The results demonstrate that immunization with two parenteral doses of 1 microg or three oral doses of 100 microg of pertussis toxoid (PTd) and filamentous haemagglutinin (FHA) encapsulated in PLG conferred a high level of protection against B. pertussis challenge. Furthermore protection could be generated with a single parenteral immunization with a combined microparticle and nanoparticle formulation. However, the route of immunization and the size of the particles affected the type of T cell response induced. Parenteral immunization with PTd and FHA entrapped in PLG microparticles elicits a potent type 1 T cell response and potent antibody response when given by the intraperitoneal (i.p.) or intramuscular (i.m.) route. In contrast, nanoparticle formulations favoured the induction of Th2 cells.


Subject(s)
Antigens, Bacterial/administration & dosage , Bordetella pertussis/immunology , Pertussis Vaccine/administration & dosage , Virulence Factors, Bordetella , Whooping Cough/immunology , Whooping Cough/prevention & control , Adhesins, Bacterial/administration & dosage , Administration, Oral , Animals , Antibodies, Bacterial/biosynthesis , Biocompatible Materials , Hemagglutinins/administration & dosage , Injections , Lactic Acid , Mice , Mice, Inbred BALB C , Microspheres , Particle Size , Polyglycolic Acid , Polylactic Acid-Polyglycolic Acid Copolymer , Polymers , Th1 Cells/immunology , Th2 Cells/immunology , Toxoids/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL